Mylan CEO: 'Considerable less' profit from generic

In this video

Share

Mylan CEO: 'Considerable less' profit from generic

Rep. Trey Gowdy (R-SC) questions Mylan CEO Heather Bresch about costs and compensation of the EpiPen and its generic equivalent at her hearing on Capitol Hill.
05:07
Wed, Sep 21 20164:41 PM EDT